As a result of the July 2020 update the FDA's guidance document, "Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use", FDA extended the TRIP program. It ended on March 31, 2021.
via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/35fzlpz
No comments:
Post a Comment